The Role of Rapid vs Conventional HIV Antibody Testing for Inpatients  

Rapid testing for HIV has improved HIV screening in the outpatient and perinatal settings, but few data report how it may be used to improve the quality of inpatient care. In the current study, researchers compared quality of care for inpatients diagnosed in the emergency department via rapid testing vs patients whose conditions were diagnosed via conventional testing during their hospital admission.

The investigators reviewed medical records to identify patients with first-time positive HIV tests and concurrent hospital admission who were tested via either rapid testing in the emergency department or conventional testing during their hospital admission. They then compared quality-of-care end points for these patients.

Results

· 103 HIV-infected inpatients were identified with no previous HIV diagnosis;

· The conditions of 48 patients (47%) were diagnosed by rapid testing and 55 (53%) by conventional testing.

· Mean length of stay was 6 days for the rapid test group vs 13 days for the conventional test group (P<.001);

· Multivariate regression analysis showed that testing modality had an independent, statistically significant effect on length of stay.

·  Nine (16%) of the patients in the conventional test group vs none in the rapid test group were discharged without receiving their HIV test results (P = .002).

· Patients in the rapid test group attended the outpatient HIV clinic in a mean of 22 days vs 50 days for the conventional test group patients (P = .05).

Based on the findings, the authors conclude, “Rapid HIV testing in the emergency department preceding admission may shorten hospital stay, increase the number of newly diagnosed patients with HIV who are discharged from the hospital aware of their HIV status, and improve entry into outpatient care for patients admitted at the time of their initial HIV diagnosis.”

Division of Infectious Diseases, Department of Internal Medicine, John H. Stroger, Jr, Hospital of Cook County, Rush University Medical Center, Ruth M. Rothstein CORE Center, and Provident Hospital of Cook County, Chicago, Ill.

10/03/05

Reference
R Lubelchek and others. The Role of Rapid vs Conventional Human Immunodeficiency Virus Testing for Inpatients: Effects on Quality of Care. Archives of Internal Medicine 165(17):1956-60. September 26, 2005.


HIV Antibody Testing and Rapid HIV Tests Articles on HIV and Hepatitis.com

At $200 - $300 per Test, When Are HIV Viral Load Assays a Bargain and Perhaps a Lifesaver? - 7/20/05

Data from 2005 HIV Prevention Conference Give Clearer Picture of HIV Epidemic in the US
- 6/15/05

Growing Acceptance of HIV Testing and Expanded Use of the HIV Rapid Test Dramatically Increase Counseling, Testing and Diagnosis of HIV
- 6/15/05

HIV Testing Should Be Offered to All Who Are Sexually Active, Researchers Say
- 4/01/05

No Time to Wait: How Many HIV Positive Gay Men Die Due to a Late Diagnosis?
- 3/30/05

The Role of Rapid Testing vs Standard Testing for HIV Among Inpatients 
- 3/30/05

Routine HIV Antibody Testing Is Cost Effective Even in Low Prevalence Populations - 02/14/05

Bio-Rad Labs Receives FDA Approval for New HIV-1 and HIV-2 Rapid Test  - 01/07/05

Rapid HIV Testing Late in Pregnancy Proves Helpful in Peruvian Expectant Mothers
- 11/22/04

Rapid HIV Test Can Provide Accurate Results for Women in Labor  - 07/14/04

Mobile HIV Testing Program Removes Barriers to HIV Testing in Africa  - 07/14/04


Some Patients Treated During Early Infection Test HIV Negative  - 07/14/04

OraSure Gets Approval in US for HIV-2 Antibody Test - 06/25/04


Patients Who Start Therapy with a CD4+ T-cell Count <200 cells/mm3 Have Poorer Immunologic Outcomes  - 06/02/04


Inadequate Host Immune System Can Lead to Seronegative HIV Infection
05/26/04

AIDS Group Urges HIV Testing in Los Angeles Bathhouses - 05/05/04

Issues in Implementation of Rapid HIV Testing - 04/02/04

FDA Approves Rapid Oral HIV Test - 03/29/04

FDA Approves Uni-Gold Recombigen, a 10-minute Rapid HIV Test - 01/05/04


Link to FDA-approved Anti-HIV Drugs
PI
NRTI
nNRTI
EI
Combivir
Emtriva
Epivir
Epzicom
Hivid
Retrovir
Trizivir
Truvada
VIDEX
VIDEX EC  
Viread

Zerit
Zerit XR
Ziagen
Rescriptor
Sustiva
Viramune
Fuzeon
Protease Inhibitors
Non Nucleoside Reverse Transcriptase Inhibitors
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
Entry / Fusion Inhibitors
Link to Experimental Medicines in Development for AIDS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

HIV/AIDS Topics
 [ A to Z ]

Abacavir Sensitivity Reaction
Acquired Drug Resistance
Acquired Rectal Fistula

Adherence
Adolescents
African Americans
Age/aging
AIDS-defining Illnesses
AIDS-related Non-Hodgkin's Lymphoma
Alcohol
Alternative Therapies
ALT/AST
Anal Intraepithelial Neoplasia (AIN)
Anemia / Fatigue
Antimycobacterial Prophylaxis
Atheroschlerosis
Aspergillosis
Autoimmune Thyroid Disease
Bacteremia
Bacterial Infections
Bartonella
Body Mass Index (BMI)
Bone Disorders
Boosted Protease Inhibitors
Breast-feeding
Buffalo Hump (BH)
Caesarean section
Candidiasis
Cancers
Cardiovascular Disease
CXCR4 Co-receptor
CCR5 Co-receptor
CD4 T Cell Count/ Percent
CD4+ and CD8 in Whole Blood
CD8+ T Cell
CD8 and CD3 Cells
Cerebrospinal Fluid (CSF)
Cholesterol / Triglycerides
Children and Infants
Central Nervous System (CNS)
Clinical Trials
CMV Retinitis
Complementary Alternative Therapies
Cosmetic Procedures
CYP3A Pathway
Cryptococcus
Cytomegalovirus
Dementia
Depression
Developing Countries
Diabetes
Diarrhea / Gastrointestinal
Dietary Intake
Directly Observed Therapy (DOT)
Disease Progression
Dosing
Drug Abuse
Drug Interactions
Drug Pricing
Drug Resistance Testing
Dyslipidemias
Elevated bilirubin and Jaundice
Elevated Creatinine Level
Entry Inhibitors
Epstein Barr Virus
Epidemiology
Eradication (HIV)
Ethnicity
Experimental Drugs
Experimental Vaccine
Facial Implants
Fat Loss
Fat Accumulation
Fat Redistribution
FDA-Approved Treatments
Fixed-dose Combinations (FDC)
Flu / Fever
Fungal Infections
Fusion or Entry Inhibitors
GB Virus C (GBC of hepatitis G)
Gender
Generics
Genetics
Genotype Resistance Testing
Glucose MetabolismInsulin Resistance
Growth Failure
Growth Hormone
Guidelines
Gynecomastia
HAART / Mega-HAART
Hairy leukoplakia
Hepatotoxicity (Liver Toxicity)
Hispanic Ethnicity
Histoplasmosis
HIV Antibody
HIV Eradication
HIV Prevalence
HIV Proviral DNA Testing
HIV p24 Antigen
HIV-related Adverse Events
HIV Replication
HIV RNA and HIV bDNA Testing
HIV Therapeutics
HIV-1 Fitness Assay
Hodgkin's Disease
Hormone Therapies
Hospice Care
Human Herpesvirus 8 (HHV-8)
Humanpapillomavirus (HPV)
Hydroxyurea (HU)
Hyperlactatemia
Hyperlipidemia
Hypersusceptibility
Hyperbilirubinemia / Jaundice
Hypertension
Hypophosphatemia
Hypothyroidism
Immunotherapy
Immune Based Therapy
Immunosuppression
Immune Restoration Disease
Immune Reconstitution Disease (IRD)
Immune Reconstitution Inflammatory Syndrome (IRIS)
Infants
Infective Endocarditis
Injection Site Reactions
Insulin Resistance
Intensification Therapy
Injection Drug Users (IDU)
Integrase Inhibitors
JC Virus
Kaposi Sarcoma
Kidney Toxicity / Failure
Kinetic PCR
Lactic Acidosis/Hyperlactatemia
Leukoencephalopathy
Lipid Abnormalties
Lipodystrophy
Liver Enzyme
Long-term Non Progression
Lung Diseases
Non-Tuberculosis Lung Diseases
Malignancies
Mega-HAART
Men Who Have Sex with Men (MSM)
Meningoencephalitis
Microbicides
Miscellaneous
Mitochondrial Toxicity
Morphologic Changes
Mortality and Morbidity
Mother-to-Child Transmission
Multidrug Resistant (MDR) HIV
Mutation Resistance
Myalgias (muscle aches)
Mycobacterium avium Complex
Myelopathy
Myocardial Infarction (MI)
Natural History
NAMs
(nucleoside-associated resistance mutations)

Nausea
Neonatal Transmission
Nephrotoxicity
Neopterin
Neurotoxicity
Neutropenia
Nevirapine-associated Rash
Nitazoxanide
Nucleic Acid Screening Test
Non-AIDS Related Hodgkin's Lymphoma
Non-Tuberculosis Lung Diseases
Non-Nucleoside Reverse Transcriptase Inhibitors (nNRTIs)
Non-occupational Post Eexposure Prophylaxis (NPEP)
NNRTI Toxicities and Side Effects Guide
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Nucleotide Reverse Transcriptase Inhibitors (NtRTIs)
Nutrition
Opportunistic Infections (OIs)
Oral OIs/ hairy leukoplakia/ warts
Pain
Palliative Care
Pancreatitis
Parasites
Pathogenesis

Pediatrics
Peripheral Neuropathy
Perinatal Transmission
Pharmacokinetics

Pharmacodynamics
Pneumonia
Pneumocystis carinii pneumonia (PCP)
Phenotype Resistance Testing
Pharmacokinetics
Progressive Multifocal Leukoencephalopathy (PML)
Pheumonia
Physical Exercise
Positron Emission Topography
Protease Assay
Proteinuria and Elevated Creatinine Level
Psychiatric (mental)
PML
Post Exposure Prophylaxis (PEP)

Post-traumatic Stress Disorder (PTSD)
Pregnancy
Prevention
Primary HIV Infection
Protease Inhibitors (PIs) / Boosted PIs
Protease Inhibitor Toxicities/Side Effects (PDF)
Public Policy
Quality of Life

Race / Ethnicity
real-time DNA PCR (RT DNA-PCR)
Renal (Kidney) Toxicity / Failure
Replication Capacity Tests
Resistance
Resistance Mutation
Resistance Testing
Resistance Training
Ritonaivr Boosted PIs
Safer Sex
Salvage Therapies
Seroconversion
Severe Adverse Drug Reactions
Sexual Dysfunction
Sexually Transmitted Diseases
Side Effects
Simplification Regimens/Trials
Skin Conditions
Smoking
Staphylococcus Aureus
Steroids
Stroke
Substance Abuse
Suicidal Ideation
Survival
Super Infection
Sustained Virological Response
Syphilis
Switch Studies
TAMs (thymidine analogue mutations)
Tat gene
Testosterone
thrombosis
Therapeutic Drug Monitoring (TDM)
Therapeutic HIV Vaccines
Thyroid Disease
Toxicities and Side Effects
Toxicities Guides
Toxoplasmosis
Transmission

Transplantation
Treatment Failure
Treatment Guidelines
Treatment Interruptions (TIs)
Tuberculosis
Undetectable HIV Viral Load
Unsafe Sex
Vaccines
Vaginal HIV Shedding
Vertical Transmission of HIV
Viral (HIV) Set Point
Viral Load (HIV RNA or HIV bDNA)
Viral Load Rebound / Increase
Virco Antivirogram
Virologic Control
Virologic Failure
Visceral Adiposity
Virtual Phenotype Resistance Testing
Wasting - HIV
White Race / Caucasian
Women